###### Strengths and limitations of this study

-   This is one of the first studies to compare the two methodologies most commonly used to obtain patterns of multimorbidity, hierarchical cluster analysis and exploratory factor analysis.

-   The dual analysis was performed in a large, high-quality database of primary care electronic health records that have been shown to be representative of a much larger population, stratified by sex.

-   Internal validation with bootstrap methods provided more robust evidence for the cluster analysis.

-   The agglomerative hierarchical clustering forces every unit into a single cluster, is exploratory in nature and different clustering algorithms may produce different results.

-   The study is cross-sectional and further studies are needed to analyse the patterns that develop longitudinally as individual patients acquire subsequent comorbidities.

Introduction {#s1}
============

The reliable identification of patterns of multimorbidity is a critical step in developing healthcare services sensitive to the health needs of these patients.[@R1] Recent reviews of multimorbidity patterns have shown that individual studies differ widely in their design and choice of epidemiological and statistical methods, including sampling frameworks and selection criteria, coding systems, eligible diseases and definition of disease clustering patterns.[@R2] These studies highlight the lack of consensus to measure patterns of comorbidity and multimorbidity. In recent years, the number of studies based on real-world data (RWD)[@R5] has increased significantly, which makes it even more difficult to establish a consensus on how to measure comorbidity and multimorbidity patterns. Although much more information is available, the different databases may not be comparable, making it difficult to arrive at observations and draw firm conclusions. It also limits our ability to compare analyses using RWD and to evaluate whether one approach may be better suited to the purpose. Therefore, it is difficult to identify multimorbidity patterns and provide adequate health services according to the population needs.

The most frequent methods used to date have been hierarchical cluster analysis (HCA) and exploratory factor analysis (EFA), which offer very different approaches and solutions.[@R2] Both are descriptive methods to identify association of diagnoses and determine patterns of multimorbidity. HCA obtains the patterns of multimorbidity from the dissimilarities between diseases, while EFA is based on correlations between diagnoses to identify the patterns. The HCA clusters tend to contain diagnoses that are similar to each other (in terms of Euclidean distances), but dissimilar from the diagnoses in other clusters; no diagnosis can be included in more than one cluster. In contrast, EFA along with confirmatory factor analysis are primarily used to test hypothesised relationships between observed measures and latent constructs. In addition, EFA allows for inclusion of any diagnosis in multiple factors as they can present significant correlations with more than one factor.[@R6]

For all these reasons, the aim was to compare multimorbidity patterns identified with the two most commonly used methods: HCA and EFA in a large primary care database. Specific objectives were (1) to determine whether choice of method affects the composition of these patterns and (2) to consider the potential application of each method in the clinical setting.

Methods {#s2}
=======

Design, setting and study population {#s2a}
------------------------------------

A cross-sectional study was conducted in Catalonia (Spain), a Mediterranean region with 7 434 632 inhabitants, 81% of which live in urban municipalities (2010 Census). The Spanish National Health Service provides universal coverage, financed mainly by tax revenue. The Catalan Health Institute (CHI) manages primary health care teams (PHCTs) that serve 5 501 784 patients (274 PHCT) or 74% of the population; the remaining PHCTs are managed by other providers. The CHI's Information System for Research in Primary Care (SIDIAP) contains the coded clinical information recorded in electronic health records (EHR) by its 274 PHCTs since 2006. A subset of records meeting the highest quality criteria for clinical data (SIDIAP-Q) includes 40% of the SIDIAP population (1 833 125 individuals), attended by the 1365 general practitioners whose data recording scores contain information on the majority of the population of Catalonia, and is highly representative for the whole region in terms of geography, age, gender and diseases.[@R10]

Prevalence of individual conditions varies with age and so does multimorbidity and their patterns. In order to obtain a more homogeneous sample in terms of multimorbidity, we focused on individuals aged 45--64 years.[@R13] We identified 408 944 individuals aged 45--64 years on 31 December 2010 with two or more diagnoses (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}).
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Coding and selection of diseases {#s2b}
--------------------------------

Diseases are coded in SIDIAP using International Classification of Diseases version 10 (ICD-10). For this study, we selected all active diagnoses recorded in EHR as of 31 December 2010, except for R codes (symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified) and Z codes (factors influencing health status and contact with health services).[@R17] Non-active diagnoses were excluded, based on the presence of an end date in the EHR. These diagnoses cover a broad list of acute diseases for which the system automatically assigns an end date (eg, 60 days after the initial diagnosis).

To facilitate management of the diagnostic information, the diagnoses were extracted using the 263 blocks (disease categories) in the ICD-10 structure. These are homogeneous categories of very closely related specific diagnoses. For example, hypertensive diseases include essential (primary) hypertension, hypertensive heart disease, hypertensive renal disease, hypertensive heart and renal disease and secondary hypertension. To obtain consistent and clinically interpretable patterns of association, and to avoid spurious relationships that could bias the results, we considered only diagnoses with greater than 1% prevalence in each sex. All patients with multimorbidity (two or more coexisting diagnoses recorded in the EHR on 31 December 2010) were included.

Variables {#s2c}
---------

The variables considered were: diagnosis (values: 1 for present, 0 for absent), number of diseases (2, 3, 4 and 5 or more) and sex (women, men) were also recorded for each patient.

Statistical analysis {#s2d}
--------------------

Data access: data were obtained from SIDIAP after the study was authorised. All the project's authors could access the database. Cleaning methods: the analysis was limited to SIDIAP-Q, as the sample was representative of the population.[@R10] No missing values were handled as sex and age were recorded for all population. Wrong sex-specific diagnoses codes and diagnoses with inconsistent dates were excluded. An individual with no disease diagnoses record was considered as disease free.

Analyses were stratified by sex. Descriptive statistics were used to summarise overall information. Categorical variables were expressed as frequencies (percentage) and continuous as mean (SD) or median (IQR). Two sample test of proportions and Mann-Whitney U test were used to test differences by sex.

We identified disease patterns using two approaches: (1) HCA and (2) EFA. Clinical criteria were used to evaluate the consistency and utility of the final HCA and EFA solutions, based on previously described patterns in the literature and a consensus opinion drawn from the clinical experience of the research team (four family physicians, one epidemiologist). Clusters and factors in these analyses were considered as two sets of grouping solutions, which were then assigned to each individual patient. We considered patients to be associated with a given grouping solution if they had ≥1 diagnoses in that solution, allowing for the calculation of the prevalence of each solution in the sample. Patients could be associated with more than one solution in the same set. We also calculated prevalence, restricting the assignment of patients to those with ≥2 diagnoses in the same solution.

### Hierarchical cluster analysis {#s2d1}

The HCA approach assigns diagnoses to groups or clusters, so that diagnoses in the same cluster are more similar, based on a given measure, to one another than to diagnoses from different clusters. The Jaccard coefficient was used to measure similarity. This coefficient considers only the diagnoses that any two patients have and ignores the diagnoses that neither of them has.[@R6] As we do not know a priori the number of clusters to retain from the data, we used agglomerative hierarchical methods to identify possible clustering solutions: average linkage, Ward, flexible beta and other methods with less bias, based on non-parametric estimates, such as single linkage and density linkage. All but Ward method and the flexible-beta methods successively chained the observations into one cluster. Therefore, the Ward method, which minimises the variance within clusters and produces clusters of similar sizes, was chosen as the primary method based on analysis.[@R6] Data were randomly split into test and training datasets, equal in size and analysed separately. We ran the Ward method on both samples. The semipartial R^2^, Calinski-Harabasz pseudo-F statistic and pseudo-T^2^ statistic criteria for different numbers of clusters were examined.[@R6] Clustering solutions were compared between the test and training datasets, taking into account the number of clusters, Adjusted Rand Index and clinical criteria. After checking algorithm stability, Ward method was run on the full data set, applying the same criteria to different numbers of clusters. Results were compared with flexible-beta results, with beta values set at −0.25 and −0.5. The criteria for selecting the number of clusters were the highest adjusted Rand index with a high number of clusters and a high pseudo T^2^ statistic.[@R6] To assess internal cluster quality, we applied multiscale bootstrap resampling to obtain an approximately unbiased (AU) probability. This probability ('P value') is the proportion of bootstrapped samples that contain the cluster; larger P values indicate more support for the cluster.[@R18]

Multidimensional scaling (MDS) considering two dimensions was used to discover the underlying structure of distance measures between diseases in the cluster analysis. Essentially, MDS assigns observations to specific locations in a conceptual space such that the distances between points in the space match the given dissimilarities as closely as possible. We carried out classical MDS using the distance matrix obtained in the cluster analysis that considered the Jaccard coefficient as a dissimilarity measure. The conceptual map of the diseases distinguishes between the intradisease cluster and the interdisease cluster. Taking into account the final cluster's solution and the obtained groups, conceptual maps of the diseases were created. For a better interpretation of the conceptual map, prevalence of the disease was represented as the radius of the circle.[@R19]

### Exploratory factor analysis {#s2d2}

EFA reduces the observed set of diagnoses to a smaller number of latent factors that account for the correlations between them. As the study variables were dichotomous, the correlation matrix between the diagnoses was computed using tetrachoric correlations. The factorability of the matrix was tested using Bartlett test of sphericity and Kaiser-Meyer-Olkin (KMO) Measure of Sampling Adequacy. The extraction of the initial solution was carried out using the principal factors method with squared multiple correlations for the prior communality estimates. The optimal number of extracted factors for the final solution was determined with the Scree plot using the 'elbow' rule and setting the percentage of variance equal to 100%. Factor loadings were analysed to identify factor patterns. An oblique rotation, Oblimin, was performed to clarify the factor pattern in order to better interpret the nature of the factors, as we assumed that factors were allowed to be associated with each other. As a rule of thumb, factor loadings greater than or equal to 0.30 in absolute value were considered to be significant.[@R7]

### Comparing multimorbidity patterns {#s2d3}

We compared every cluster and factor solutions across sex groups agreement and the diagnoses included in it.

We considered grouping solutions (HCA vs EFA) from different sets (women vs men) to have the following degrees of similarity: (1) perfect, when the solution included exactly the same diseases as another solution in the other comparison group (sex or statistical approach); (2) partial, when the solution included a subset of diseases present in a solution in the other comparison group and (3) none, when each and every disease in the solution was part of a different solution in the other group and none was part of the same solution. These groups were named using the abbreviation of sex, method and number (eg, MC1: men cluster 1).

We further extracted the common subsets of diseases within partially similar solutions, which together with completely similar solutions gave a comprehensive picture of overlapping cluster and factor analysis solutions.

The analyses were performed using SPSS for Windows, V.18, SAS V.9.2 for Windows and R V.3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#s3}
=======

Of 523 656 patients, 408 994 (78.1%) met the multimorbidity criteria; women had a higher multimorbidity prevalence than men (82.2% vs 73.9%, respectively; P\<0.001) ([table 1](#T1){ref-type="table"}). Both cluster and factor analyses included 79 diagnoses for women and 73 for men.

###### 

Number of diseases, clusters and factors identified in cluster and factorial analysis for patients agec 45--64 years, stratified by sex (n=523 656)

  Total, n (%)                              Women, n (%)      Men, n (%)
  ----------------------------------------- ----------------- ----------------
  ≥2 diagnoses\* 408 994 (78.1%)            217 823 (82.2)    191 171 (73.9)
  No of diagnoses\*                                           
   2                                        26 106 (12.0)     33 850 (17.7)
   3                                        28 243 (13.0)     33 515 (17.5)
   4                                        28 274 (13.0)     30 356 (15.9)
   ≥5                                       1 35 200 (62.1)   93 450 (48.9)
  Median no of diagnoses (IQR)†             5 (4--8)          4 (3--7)
  No of diagnoses included                  79                73
  No of clusters                            53                15
  No of clusters with ≥2 diagnoses          12                15
  Median of diagnoses per clusters (IQR)‡   2 (2--4)          5 (2.5--6)
  No of factors                             9                 10
  N of factors with ≥2 diagnoses            8                 9
  Median of diagnoses per factor (IQR)‡     5.5 (2.75--7)     4 (4--5)

\*Two sample test of proportions; all P\<0.001.

†Mann-Whitney U test; P\<0.001.

‡Median of clusters or factors with ≥2 diseases; P\<0.001.

Hierarchical cluster analysis {#s3a}
-----------------------------

Using HCA with the Ward method, we obtained 53 clusters, with just 12 clusters grouping at least 2 diagnoses for women and 15 clusters for men ([table 1](#T1){ref-type="table"}). We describe only the four most prevalent clusters ([table 2](#T2){ref-type="table"}). For a complete description of the clusters and dendrograms, see online [supplementary appendices 2--5](#SP2 SP3 SP4 SP5){ref-type="supplementary-material"}.

###### 

Four most prevalent clusters, by sex group (N (women)=217 823; N (men)=191 171)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prevalence   Prevalence                                                                                        Blocks of diagnoses                                                            Prevalence in group‡,   Prevalence in cluster,   AU P value§
  ------------ ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------- ------------------------ -------------------
  Women                                                                                                                                                                                                                                          

  WC1¶         52.9                                                                                              M50--M54: other dorsopathies                                                   35.8                    43.5                     0.79 (0.74--0.85)

  82.1         F40--F48: neurotic, stress-related and somatoform disorders                                       27.3                                                                           33.2                                             

               M70--M79: other soft-tissue disorders                                                             27.0                                                                           32.8                                             

               N80--N98: non-inflammatory disorders of female genital tract                                      24.2                                                                           29.5                                             

               M20--M25: other joint disorders                                                                   18.6                                                                           22.6                                             

               I80--I89: diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified          18.3                                                                           22.2                                             

               D10--D36: benign neoplasms                                                                        16.2                                                                           19.7                                             

               M15--M19: arthrosis                                                                               15.7                                                                           19.1                                             

  WC2          23.0                                                                                              E70--E90: metabolic disorders                                                  37.4                    63.4                     0.93 (0.86--1.00)

  55.8         I10--I15: hypertensive diseases                                                                   25.6                                                                           45.8                                             

               E65--E68: obesity and other hyperalimentation                                                     19.0                                                                           34.0                                             

               E10--E14: diabetes mellitus                                                                       7.7                                                                            13.7                                             

  WC3\         10.8                                                                                              F10--F19: mental and behavioural disorders due to psychoactive substance use   18.7                    39.4                     0.78 (0.73--0.84)
  47.4                                                                                                                                                                                                                                           

               E00--E07: disorders of thyroid gland                                                              14.9                                                                           31.4                                             

               F30--F39: mood (affective) disorders                                                              14.6                                                                           30.8                                             

               M80--M85: disorders of bone density and structure                                                 11.3                                                                           23.9                                             

  WC4          6.4                                                                                               J00--J06: acute upper respiratory infections                                   12.6                    39.1                     0.71 (0.66--0.77)

  32.3         K00--K14: diseases of oral cavity, salivary glands and jaws                                       12.1                                                                           37.3                                             

               L20--L30: dermatitis and eczema                                                                   9.3                                                                            28.8                                             

               B35--B49: mycoses                                                                                 5.7                                                                            17.8                                             

  Men                                                                                                                                                                                                                                            

  MC1\*\*      50.4                                                                                              E70--E90: metabolic disorders                                                  42.2                    50.3                     0.69 (0.64--0.75)

  83.8         F10--F19: mental and behavioural disorders due to psychoactive substance use                      33.6                                                                           40.1                                             

               I10--I15: hypertensive diseases                                                                   32.5                                                                           38.8                                             

               M50--M54: other dorsopathies                                                                      27.8                                                                           33.2                                             

               E65--E68: obesity and other hyperalimentation                                                     14.6                                                                           17.4                                             

               E10--E14: diabetes mellitus                                                                       14.2                                                                           16.9                                             

  MC2          24.2                                                                                              M70--M79: other soft tissue disorders                                          16.9                    29.3                     0.87 (0.84--0.90)

  57.6         N40--N51: diseases of male genital organs                                                         12.1                                                                           21.0                                             

               M20--M25: other joint disorders                                                                   12.1                                                                           20.9                                             

               K20--K31: diseases of oesophagus, stomach and duodenum                                            11.5                                                                           20.0                                             

               I80--I89: diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified          10.0                                                                           17.4                                             

               K40--K46: hernia                                                                                  8.8                                                                            15.2                                             

               D10--D36: benign neoplasms                                                                        8.6                                                                            14.9                                             

               M15--M19: arthrosis                                                                               7.7                                                                            13.4                                             

               K55--K63: other diseases of intestines                                                            6.4                                                                            11.1                                             

  MC3          20.7                                                                                              F40--F48: neurotic, stress-related and somatoform disorders                    13.5                    24.9                     0.79 (0.74--0.84)

  54.1         K00--K14: diseases of oral cavity, salivary glands and jaws                                       12.0                                                                           22.3                                             

               J40--J47: chronic lower respiratory diseases                                                      9.3                                                                            17.2                                             

               J00--J06: acute upper respiratory infections                                                      8.9                                                                            16.4                                             

               J30--J39: other diseases of upper respiratory tract                                               8.0                                                                            14.8                                             

               L20--L30: dermatitis and eczema                                                                   7.5                                                                            13.9                                             

               G40--G47: episodic and paroxysmal disorders                                                       7.4                                                                            13.7                                             

               F50--F59: behavioural syndromes associated with physiological disturbances and physical factors   6.6                                                                            12.2                                             

               F30--F39: mood (affective) disorders                                                              6.3                                                                            11.6                                             

               B35--B49: mycoses                                                                                 4.1                                                                            7.6                                              

  MC4          4.7                                                                                               H90--H95: other disorders of ear                                               7.7                     30.6                     0.87 (0.83--0.91)

  25.2         H53--H54: visual disturbances and blindness                                                       3.9                                                                            15.5                                             

               B00--B09: viral infections characterised by skin and mucous membrane lesions                      3.5                                                                            13.9                                             

               L60--L75: disorders of skin appendages                                                            3.5                                                                            13.9                                             

               H10--H13: disorders of conjunctiva                                                                3.0                                                                            12.0                                             

               H49--H52: disorders of ocular muscles, binocular movement, accommodation and refraction           2.8                                                                            11.2                                             

               L80--L99: other disorders of the skin and subcutaneous tissue                                     2.5                                                                            10.0                                             

               L00--L08: infections of the skin and subcutaneous tissue                                          2.1                                                                            8.3                                              

               H00--H06: disorders of eyelid, lacrimal system and orbit                                          1.6                                                                            6.5                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Individuals from the strata ≥1 diagnosis in the cluster.

†Individuals from the strata with ≥2 diagnosis in the cluster.

‡Strata: same sex.

§Approximately unbiased (AU) probability value.

¶Abbreviation of sex, method and number (WC1: women cluster 1).

\*\*Abbreviation of sex, method and number (MC1: men cluster 1).

Twelve clusters with at least two diseases were identified for women, with prevalences ranging from 6.6% to 82.1% (median: 15.5%), (WC3; WC10). The clusters identified in men had prevalences ranging from 3.2% to 83.8% (median 10.1%). The most prevalent cluster included eight diseases in women (WC1: musculoskeletal, psychiatric, circulatory, gynaecological and neoplasms) and six in men (MC1: metabolic and circulatory); about half of all patients had at least two diagnoses (52.9% of women and 50.4% of men).

Two clusters were common to men and women, 'spondylopathies' and 'deforming dorsopathies' (WC11, MC13) and 'urolithiasis' and 'other diseases of the urinary systems' (WC9, MC12) ([box 1](#B1){ref-type="boxed-text"}). The remaining clusters showed partial similarity in men and women, based on six subsets ([box 2](#B2){ref-type="boxed-text"}), except for three clusters found only in women (WC3, WC7, WC10) and six only in men (MC4, MC5, MC8, MC10, MC14, MC15) (online [supplementary appendices 4--5)](#SP4 SP5){ref-type="supplementary-material"}.Box 1Combinations of diseases consistent in both men and women\*ClustersComplete (whole) clustersM45--M49: spondylopathies†M40--M43: deforming dorsopathies (WC11; MC13)‡N20--N23: urolithiasisN30--N39: other diseases of urinary system (WC9; MC12)Subsets within clustersE65--E68: obesity and other hyperalimentationI10--I15: hypertensive diseasesE10--E14: diabetes mellitus (WC2; MC1)M15--M19: arthrosisM20--M25: other joint disordersI80--I89: diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedM70--M79: other soft tissue disordersD10--D36: Bbenign neoplasms (WC1; MC2)L20--L30: dermatitis and eczemaB35--B49: mycosesK00--K14: diseases of oral cavity, salivary glands and jawsJ00--J06: acute upper respiratory infections (WC4; MC3)K70--K77: diseases of liverK80--K87: disorders of gallbladder, biliary tract and pancreas (WC12; MC7)J30--J39: other diseases of upper respiratory tractJ40--J47: chronic lower respiratory diseases (WC6; MC3)K20--K31: diseases of oesophagus, stomach and duodenumK40--K46: hernia (WC5; MC2)G50--G59: nerve, nerve root and plexus disordersM65--M68: disorders of synovium and tendon (WC8; MC6)Factors\*Subgroups within factorsI10--I15: hypertensive diseasesI20--I25: Iischaemic heart diseasesI30--I52: other forms of heart diseaseI70--I79: diseases of arteries, arterioles and capillaries (WF3; MF2)I10--I15: hypertensive diseasesE65--E68: obesity and other hyperalimentation (WF2; MF1)J00--J06: acute upper respiratory infectionsJ20--J22: other acute lower respiratory infectionsJ09--J18: influenza and pneumoniaB25--B34: other viral diseasesA00--A09: intestinal infectious diseases (WF4; MF6)M15--M19: arthrosisM45--M49: spondylopathiesM40--M43: deforming dorsopathiesM50--M54: other dorsopathies (WF1; MF4)K20--K31: diseases of oesophagus, stomach and duodenumQ38--Q45: other congenital malformations of the digestive system (WF6; MF8)L20--L30: dermatitis and eczemaB35--B49: mycosesH53--H54: visual disturbances and blindnessH10--H13: disorders of conjunctivaL80--L99: other disorders of the skin and subcutaneous tissue (WF5; MF5)H25--H28: ddisorders of lensH30--H36: disorders of choroid and retina (WF3; MF7)[^1][^2][^3][^4] Box 2Combinations of diseases consistent across statistical methods (cluster and factor analysis)\*WomenI10--I15: hypertensive diseases†E65--E68: obesity and other hyperalimentationE10--E14: diabetes mellitus (WC2; WF2)‡M15--M19: arthrosisM50--M54: other dorsopathiesM70--M79: other soft-tissue disorders (WC1; WF1)L20--L30: dermatitis and eczemaB35--B49: mycoses (WC4; WF5)M45--M49: spondylopathiesM40--M43: deforming dorsopathies (WC11; WF1)K20--K31: diseases of oesophagus, stomach and duodenumK40--K46: hernia (WC5; WF6)K70--K77: diseases of liverK80--K87: disorders of gallbladder, biliary tract and pancreas (WC12; WF6)MenI10--I15: hypertensive diseasesE65--E68: obesity and other hyperalimentationE70--E90: metabolic disorders (MC1; MF1)I20--I25: ischaemic heart diseasesI30--I52: other forms of heart diseaseI60--I69: cerebrovascular diseasesI70--I79: diseases of arteries, arterioles and capillariesN17--N19: renal failure (MC5; MF2)J09--J18: influenza and pneumoniaJ20--J22: other acute lower respiratory infectionsB25--B34: other viral diseasesA00--A09: intestinal infectious diseases (MC10; MF6)H10--H13: disorders of conjunctivaH53--H54: visual disturbances and blindnessL80--L99: other disorders of the skin and subcutaneous tissue (MC4; MF5)M45--M49: spondylopathiesM40--M43: deforming dorsopathies (MC13; MF4)L20--L30: dermatitis and eczemaB35--B49: mycoses (MC3; MF5)K70--K77: diseases of liverB15--B19: viral hepatitis (MC7; MF3)T08--T14: injuries to unspecified part of trunk, limb or body regionS90--S99: injuries to the ankle and foot (MC8; MF9)H25--H28: disorders of lensH40--H42: glaucoma (MC14; MF7)[^5][^6][^7][^8]

The top four clusters were reproduced in the graphical representation of coordinates using MDS. The most prevalent disease clusters were more clearly separated in women than they were in men, mostly due to the overlap of MC2 and MC3 ([figure 1](#F1){ref-type="fig"}).

![(A) Top four clusters in women (n=217 823) aged 45--64 years, analysed with multidimensional scaling (MDS). (B) Top four clusters in men (n=191 171) aged 45--64 years, analysed with MDS.](bmjopen-2017-018986f01){#F1}

Exploratory factor analysis {#s3b}
---------------------------

Using EFA, we obtained 9 factors for women and 10 factors for men. In this analysis, the median number of diagnoses per factor was higher in women ([table 1](#T1){ref-type="table"}). Two factors explained more than 50% of total variance (58.5% for women (WF2; WF3) and 50.7% for men (MF1; MF2)). All diseases were assigned to single factors except for three diseases, two in women only (J20--J22: other acute lower respiratory infections and E10--E14: diabetes mellitus) and one in both women and men (I10--I15: hypertensive diseases); all three were assigned to two factors. The first four factors are described in [table 3](#T3){ref-type="table"}; full factor solutions are shown in online [supplementary appendices 6--7](#SP6 SP7){ref-type="supplementary-material"}.

###### 

Four most prevalent factors, by sex (N (women)=217 823; N (men)=191 171)

  Prevalence 1, %\*                                               Prevalence 2, %†   Blocks of diagnoses‡                                                           Prevalence in group,   Prevalence in factor,   Variance proportion, %   Cumulative variance proportion,
  --------------------------------------------------------------- ------------------ ------------------------------------------------------------------------------ ---------------------- ----------------------- ------------------------ ---------------------------------
  Women                                                                                                                                                                                                                                     
  WF1§ 59.7                                                       25.4               M50--M54: other dorsopathies                                                   35.8                   59.9                    10.6                     69.1
  M70--M79: other soft-tissue disorders                           27.0               45.2                                                                                                                                                   
  M15--M19: arthrosis                                             15.7               26.2                                                                                                                                                   
  G50--G59: nerve, nerve root and plexus disorders                8.5                14.3                                                                                                                                                   
  M45--M49: spondylopathies                                       4.3                7.3                                                                                                                                                    
  M40--M43: deforming dorsopathies                                3.8                6.4                                                                                                                                                    
  WF2 37.8                                                        12.0               I10--I15: hypertensive diseases                                                25.6                   67.6                    7.0                      84.5
  E65--E68: obesity and other hyperalimentation                   19.0               50.2                                                                                                                                                   
  E10--E14: diabetes mellitus                                     7.7                20.3                                                                                                                                                   
  WF3 32.8                                                        8.1                I10--I15: hypertensive diseases                                                25.6                   78.0                    20.2                     58.6
  E10--E14: diabetes mellitus                                     7.7                23.4                                                                                                                                                   
  I30--I52: other forms of heart disease                          4.4                13.3                                                                                                                                                   
  H25--H28: disorders of lens                                     1.7                5.3                                                                                                                                                    
  H30--H36: disorders of choroid and retina                       1.2                3.6                                                                                                                                                    
  I70--I79: diseases of arteries, arterioles and capillaries      1.1                3.2                                                                                                                                                    
  I20--I25: ischaemic heart diseases                              1.0                3.1                                                                                                                                                    
  WF4 27.6                                                        5.9                J00--J06: acute upper respiratory infections                                   12.6                   45.8                    38.3                     38.3
  N30--N39: other diseases of urinary system                      5.9                21.3                                                                                                                                                   
  H60--H62: diseases of external ear                              3.6                13.1                                                                                                                                                   
  J20--J22: other acute lower respiratory infections              3.4                12.2                                                                                                                                                   
  A00--A09: intestinal infectious diseases                        2.7                10.0                                                                                                                                                   
  H65--H75: diseases of middle ear and mastoid                    2.5                9.2                                                                                                                                                    
  J09--J18: influenza and pneumonia                               1.7                6.1                                                                                                                                                    
  B25--B34: other viral diseases                                  1.3                4.8                                                                                                                                                    
  M60--M63: disorders of muscles                                  1.2                4.4                                                                                                                                                    
  Men                                                                                                                                                                                                                                       
  MF1¶ 61.7                                                       26.1               E70--E90: metabolic disorders                                                  42.2                   68.3                    5.1                      94.8
  I10--I15: hypertensive diseases                                 32.6               52.7                                                                                                                                                   
  E65--E68: obesity and other hyperalimentation                   14.6               23.6                                                                                                                                                   
  M05--M14: inflammatory polyarthropathies                        5.4                8.7                                                                                                                                                    
  MF2 39.4                                                        8.7                I10--I15: hypertensive diseases                                                32.5                   82.6                    28.5                     28.5
  I30--I52: other forms of heart disease                          6.9                17.6                                                                                                                                                   
  I20--I25: ischaemic heart diseases                              5.0                12.6                                                                                                                                                   
  I70--I79: diseases of arteries, arterioles and capillaries      2.4                6.1                                                                                                                                                    
  I60--I69: cerebrovascular diseases                              1.8                4.6                                                                                                                                                    
  N17--N19: renal failure                                         1.5                3.7                                                                                                                                                    
  MF3 38.5                                                        4.4                F10--F19: mental and behavioural disorders due to psychoactive substance use   33.6                   87.2                    5.3                      89.6
  K70--K77: diseases of liver                                     5.2                13.6                                                                                                                                                   
  B15--B19: viral hepatitis                                       3.2                8.4                                                                                                                                                    
  F20--F29: schizophrenia, schizotypal and delusional disorders   1.1                2.9                                                                                                                                                    
  MF4 34.7                                                        5.1                M50--M54: other dorsopathies                                                   27.8                   80.2                    7.3                      77.8
  M15--M19: arthrosis                                             7.7                22.2                                                                                                                                                   
  M45--M49: spondylopathies                                       3.1                8.8                                                                                                                                                    
  M40--M43: deforming dorsopathies                                1.8                5.2                                                                                                                                                    

Kaiser-Meyer-Olkin sampling adequacy index was 0.82 for women and 0.75 for men. Bartlett test of sphericity was statistically significant. (P\<0.001) for both groups.

\*Individuals from the strata ≥1 diagnosis in the factor.

†Individuals from the strata with ≥2 diagnosis in the factor.

‡Strata: same sex.

§Abbreviation of sex, method and number (WF1: women factor 1).

¶Abbreviation of sex, method and number (MF1: men factor 1).

Although no factor-based groupings were identical in men and women, almost all showed partial similarity by sex, based on seven subsets (), except for two groups found only in women (WF7, WF9) and one found only in men (MF9).

Multimorbidity patterns comparison across statistical approaches {#s3c}
----------------------------------------------------------------

The EFA multimorbidity patterns were more easily interpreted than the HCA groups, either because they made more sense from a clinical perspective or because of greater homogeneity in the diagnoses: about half of the factors containing at least three diagnoses corresponded to a maximum of two ICD-10 blocks, compared with about one-fifth of the HCA clusters with at least three diseases (1/5 for women and 2/11 for men). No grouping solution for women or for men contained exactly the same set of diseases as a cluster and as a factor. Six clusters (WC3, WC6, WC7, WC8, WC9, WC10) and two factors (WF7, WF9) were only observed in women. However, six subsets of diseases were part of the same grouping in both a cluster and a factor ([box 2](#B2){ref-type="boxed-text"}); all included two or three diagnoses, usually from the same ICD chapter. Five clusters and one factor were observed only in men (MC6, MC9, MC11, MC12, MC15 and MF6). Nine subsets of diseases were observed as part of the same grouping in both a cluster and a factor ([box 2](#B2){ref-type="boxed-text"}). They included a range of diseases (2--5) and most frequently included diseases from different ICD chapters.

Three paired diseases were observed consistently in both men and women using both methods of analysis: (1) hypertensive diseases and obesity/other hyperalimentation; (2) spondylopathies and deforming dorsopathies and (3) dermatitis/eczema and mycoses.

Discussion {#s4}
==========

In this study have observed differences in the groupings identified with the two most frequently used methods (HCA and EFA). No grouping solution contained exactly the same set of diseases as a cluster and as a factor, although some overlap was observed in both groups. Internal quality validation with AU P values showed strong evidence of the multimorbidity patterns in the data.

The multimorbidity patterns obtained by HCA were identified graphically with MDS, allowing us to observe a given hierarchical structure. Nevertheless, internal quality validation with AU P values showed strong evidence of the multimorbidity patterns in the data.

EFA, based on tetrachoric correlations where the dichotomous diseases were assumed to come from an underlying mechanism with a continuous variable, produced a wide range of multimorbidity patterns with several levels of correlations. Most of them seem to be highly consistent from a clinical perspective. The multimorbidity patterns obtained with EFA show a main factor (a disease) that has a correlation with another disease, either coexisting or that may occur during the patient's clinical course.[@R20] Thus, EFA could be more useful for analysing comorbidity and for describing the correlation between diseases that have a pathophysiological relationship. This approach also may help to answer the question of which condition should be considered the main disease and which the comorbidity.

The HCA results would be useful in generating new hypotheses for intercluster and intracluster associations between diseases that could be applied to the analysis of multimorbidity, defined as the random coexistence of diseases or clusters that indicates significant associations between diseases without a causal explanation. In future studies, other non-HCA techniques will improve measurement of the observed distances and multiple interrelationships between different diseases in a given individual.[@R21] On the other hand, EFA could be more useful for analysing multimorbidity patterns in the absence of causal comorbidity and for describing visual representation of diseases correlation with a pathophysiological relationship between them.

We obtained two perfect clusters that were common to both men and women: 'spondylopathies and deforming dorsopathies' and 'urolithiasis and other diseases of the urinary system'. In the first cluster, spondylosis is a degenerative disorder that may cause loss of normal spinal structure and function and lead to scoliosis. Nevertheless, many individuals with untreated scoliosis will develop spondylosis; this may be one reason why these diseases were associated.[@R22] The second cluster can be explained by the complications produced by urolithiasis (such as urinary tract infection, persistent proteinuria, stress incontinence or other unspecified urinary incontinence) and those that have a pathophysiological explanation.[@R23] EFA showed that the most frequent pattern in women was infectious diseases. This previously unreported pattern suggests that the multimorbidity patterns obtained in other studies are affected by the type of diseases included in each study.

Although the patterns obtained with both methods did not match exactly, finding matching pairs of diseases by both methods reinforces the idea that patterns of multimorbidity have a dominant disease that associates in some way with other diseases.

In general, it is difficult to compare our results with other studies because of variations in methods, data sources and structures, and populations and diseases studied. Six studies have been performed with HCA[@R8] and three using EFA.[@R28] Until now, very few analyses of multimorbidity patterns have used multiple methods to compare the same population.[@R21] The latter study included people aged 50 years and older, considering 11 diseases and using two different cluster methods, hierarchical (average linkage) and non-hierarchical (k-medoids), and one method for EFA (principal component analysis). The observed differences between this study and our results can be explained by differences in the underlying statistical formulae and diseases considered in both studies.

The major strength of this study is the dual analysis (HCA and EFA) of a large, high-quality database of primary care records that have been shown to be representative of a much larger population, stratified by sex. Admittedly, this analysis of almost all potential diagnoses may have added a complexity that will hinder interpretation of findings and comparison with other studies, particularly because the boundaries between chronic and acute disease are not always clear.[@R31] Whatever consistency (or discrepancy) we observed was validated by the findings of two different approaches, which helps to identify the most appropriate use of each method in analysing multimorbidity. We emphasise that the inclusion of chronic and acute diseases is a strength and not a weakness. Because, as we have shown, there are many chronic and acute diseases that coexist at a set time and this has implications for healthcare.

Internal validation with bootstrap methods, AU P values and MDS techniques provided more robust evidence for the cluster analysis. The KMO values obtained show the adequacy of fit of the factor analysis. These values were similar or higher than previous studies.[@R28]

A limitation of this study is our use of agglomerative hierarchical clustering, which forces every unit (ie, diagnosis) into a single cluster. HCA is exploratory in nature, and different clustering algorithms may produce different results.[@R33] The final clustering solution presented here was obtained through a systematic and rigorous process: comparing the results from a randomly split dataset, testing different clustering algorithms, and using different objective numeric criteria to decide the number of clusters, internal validation and graphical representation. In addition, a panel of experts applied subjective clinical criteria to assess the interpretability of the groupings in everyday practice. In addition, EFA is problematic for binary data, which can be grouped because of having similar distributions rather than any common underlying feature. On the other hand, in factor analysis the measure of association incorporates information on both positive and negative concordances.[@R9] In contrast, the analysis of clusters allows us to show that the occurrence of one or more health conditions can be conditioned by their co-occurrence, without considering negative concordances.[@R8] Due to the absence of a standard methodology to compare method solutions, we have used ad hoc methodology. Finally, another limitation is our use of ICD-10 3-character codes as the unit of analysis, rather than the more specific individual diagnosis, but its use is justified to avoid spurious relationships that more than 10 000 individual codes of the ICD-10 could produce.

This is a cross-sectional study, based on EHR of The CHI and SIDIAP-Q is highly representative for the whole region in terms of both geography, age, gender and diseases, that avoid selection bias.

Multimorbidity can present a problem for health services delivery, affecting patients, health professionals and managers who are attempting to improve service delivery. Our study offers two methodological approaches to understanding the relationships between specific diseases, which is an essential step in improving our approach to this problem. Although we demonstrated that different analytical methods can yield different results, we also showed that some associations were consistent in both analyses. This study illustrates the need to pay careful attention to the methods used to support policies and decision-making. Clinical guidelines tend to focus on a single disease rather than on multimorbidity, which includes diseases and drug interactions and polypharmacy. The present study confirmed that multimorbidity patterns are a reality in the adult population, and do not apply only to chronic diseases. New guidelines are needed that incorporate multimorbidity into clinical recommendations.

This study was one of the first to compare the two most commonly used methodologies, HCA and EFA, in a large database that includes a large number of diseases. The findings reveal another limitation to be taken into account in comparing multimorbidity patterns between studies: in addition to the spectrum, number and type of diseases included, these patterns vary depending on the method of analysis used. Nevertheless, it would be necessary to carry out a simulation study to determine how the choice of method may affect the patterns, as it allows us to test the obtained patterns in all kinds of situations.

The results suggest that HCA can be useful to detect multimorbidity patterns and identify different associations between diseases, as the method allows for the possibility that one or more health problems can occur conditionally. On the other hand, EFA seems more applicable to clinical practice because places less restrictions in the diseases grouping, so may be better for identifying clinical associations. Our results suggest that these aspects must be considered in planning of future studies, including selection of diseases and methods of analysis.

Finally, our analysis of multimorbidity patterns only considered associations between diseases. Further studies are needed to analyse the patterns that develop longitudinally as individual patients acquire subsequent comorbidities.

Conclusions {#s5}
===========

The multimorbidity patterns obtained with EFA show a main factor (ie, a disease) that has some correlation with the additional diseases in the pattern, suggesting a comorbidity relationship. Meanwhile, the HCA would be useful for in-depth study of multimorbidity pattern. We introduced new evidence about the known limitations of attempts to compare multimorbidity or comorbidity patterns between RWD studies, as our results add information about aspects that must be considered in standardisation of future studies: spectrum of diseases, data usage and methods of analysis.
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[^1]: Underlined blocks of diagnosis represent coincident diseases in pattern.

[^2]: \*No two full factors were exactly the same for both sexes.

[^3]: †Coincident disease in both sexes.

[^4]: ‡Abbreviation of sSex (W,: wWomen; M:, mMen), method (C:, hHierarchical Ccluster aAnalysis; F:, Ffactor Aanalysis) and number (eg,.q, WC1: wWomen Ccluster 1).

[^5]: Underlined blocks of diagnosis represent coincident diseases in pattern.

[^6]: \*All subgroups of factors or clusters, no single cluster exactly the same as a factor.

[^7]: †Coincident disease in both methods.

[^8]: ‡Abbreviation of sex (W, women; M, men), method (C, hierarchical cluster analysis; F, factor analysis) and number (eg, WC1: women cluster 1).
